Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 14.18% is 122% above its 5-year average of 6.40%, near the high end of its 5-year range (-0.54%–14.18%).
As of the fiscal period ended Wednesday, December 31, 2025. 38.82% above its 12-month average of 10.21%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
14.18%
RETURN ON EQUITY (ROE) AVG TTM
10.21%
RETURN ON EQUITY (ROE) AVG 3Y
8.16%
RETURN ON EQUITY (ROE) AVG 5Y
6.40%
RETURN ON EQUITY (ROE) AVG 10Y
8.57%
RETURN ON EQUITY (ROE) AVG 15Y
3.66%
RETURN ON EQUITY (ROE) AVG 20Y
2.16%
CURRENT VS TTM AVG
+38.82%
CURRENT VS 3Y AVG
+73.67%
CURRENT VS 5Y AVG
+121.68%
CURRENT VS 10Y AVG
+65.50%
CURRENT VS 15Y AVG
+287.43%
CURRENT VS 20Y AVG
+557.84%
SECTOR MEDIAN · HEALTHCARE
10.61%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+33.65%
vs the sector median at left
Boston Scientific Corporation
Market Cap
$72.97B
Return on Equity (ROE)
14.18%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
Market Cap
$72.42B
Return on Equity (ROE)
15.05%
TTM Avg
11.32%
3Y Avg
12.19%
5Y Avg
12.83%
Market Cap
$78.36B
Return on Equity (ROE)
11.15%
TTM Avg
14.72%
3Y Avg
15.95%
5Y Avg
23.11%
Market Cap
$81.98B
Return on Equity (ROE)
11.06%
TTM Avg
13.69%
3Y Avg
14.71%
5Y Avg
14.93%
Market Cap
$61.63B
Return on Equity (ROE)
4.72%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$59.59B
Return on Equity (ROE)
75.01%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
Market Cap
$86.76B
Return on Equity (ROE)
-112.56%
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$54.70B
Return on Equity (ROE)
-56.13%
TTM Avg
-41.33%
3Y Avg
9.62%
5Y Avg
-22.30%
Market Cap
$51.59B
Return on Equity (ROE)
9.73%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Boston Scientific Corporation (BSX) | $72.97B | 14.18% | 10.21% | 8.16% | 6.40% |
| Cigna Corporation (CI)vs › | $72.42B | 15.05% | 11.32% | 12.19% | 12.83% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $78.36B | 11.15% | 14.72% | 15.95% | 23.11% |
| Elevance Health Inc. (ELV)vs › | $81.98B | 11.06% | 13.69% | 14.71% | 14.93% |
| Becton, Dickinson and Company (BDX)vs › | $61.63B | 4.72% | 6.60% | 6.50% | 6.42% |
| Cencora, Inc. (COR)vs › | $59.59B | 75.01% | 168.34% | -32.99% | 148.52% |
| HCA Healthcare, Inc. (HCA)vs › | $86.76B | -112.56% | -171.53% | -210.62% | -155.29% |
| Cardinal Health, Inc. (CAH)vs › | $54.70B | -56.13% | -41.33% | 9.62% | -22.30% |
| Edwards Lifesciences Corporation (EW)vs › | $51.59B | 9.73% | 26.07% | 24.86% | 23.86% |
| McKesson Corporation (MCK)vs › | $97.23B | -219.24% | -189.06% | -180.53% | 3473.86% |
ROE
14.2%
ROA
8.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 11.91% |
| 2024-12-31 | 8.52% |
| 2023-12-31 | 8.26% |
| 2022-12-31 | 3.97% |
| 2021-12-31 | 6.26% |
| 2020-12-31 | -0.54% |
| 2019-12-31 | 33.87% |
| 2018-12-31 | 19.15% |
| 2017-12-31 | 1.48% |
| 2016-12-31 | 5.15% |
| 2015-12-31 | -3.78% |
| 2014-12-31 | -1.74% |
| 2013-12-31 | -1.85% |
| 2012-12-31 | -59.21% |
| 2011-12-31 | 3.88% |
| 2010-12-31 | -9.43% |
| 2009-12-31 | -8.33% |
| 2008-12-31 | -15.50% |
| 2007-12-31 | -3.28% |
| 2006-12-31 | -23.38% |
| 2005-12-31 | 14.67% |
| 2004-12-31 | 26.39% |
| 2003-12-31 | 16.49% |
| 2002-12-31 | 15.12% |
| 2001-12-31 | -2.68% |
| 2000-12-31 | 19.28% |
| 1999-12-31 | 21.52% |
| 1998-12-31 | -32.20% |
| 1997-12-31 | 14.12% |
| 1996-12-31 | 18.24% |
